fitter and would make one work quicker and more skillful even when in good and normal health.
The habit of taking a few "stimulating" powders throughout the working day started at the factory of the Husqvarna Company, to keep up the output of work and to increase earnings.
The largely male work force made products ranging from sports-guns and sewing machines to motor cycles and other hardware. Since the powders could be obtained over the counter without a prescription the increasing consumption went largely unnoticed by the medical profession.
The analgesic habit spread into the town and soon many families could not think of beginning the day without the magic powder of Hjorton... It became common in the community to offer somebody a box of powders as a birthday present or to offer somebody a powder instead of a cigarette...
The practice spread further into the nearby town of .Jonkopinq and even to other more distant areas in Swe den: "Hjorton's powder gradually became known throughout the country". The doctors tended to see it as something unusual, but rather harmless, regarding it as an amusing if undesiderable habit (5) .
The bill came later. Years, even decades later the death rate from uremia and the number of kidney patients in the affected areas started to increase and rose to such an extent that both the populations, the doctors and the health authorities, in particular in the afflicted areas (Husqvarna and .Jonkopinq) became increasingly disturbed and suspicion rose of some hitherto unknown or undetected cause.
An investigation was started to evaluate the causes of death at the town of Husqvarna for the 10 year period from 1952-1961. Some 10 years earlier in 1950 Spuhler (a clinical investigator) and Zollinger (a pathologist). both from Zurich, Switzerland, reported on an at that time uncommon chronic kidney disease with an insidious, slowly progressive course, often, after years, fatally ending in uremia.
The pathological picture was a chronic interstitial nephritis with cellular infiltration of the interstitium and with interstitial fibrosis. In approximately half of the autopsied cases the authors noted papillary necrosis, a ra-ther uncommon feature which differentiated the observed type of nephropathy from other forms of chronic interstitial nephritis (6, 7) . At first the etiology remained unknown.
In 1953, however, the Swiss investigators reported a striking increase in cases: until 1948 only a few sporadic cases were observed (8) and in 1950 only 12 cases out of 20,000 autopsies were noted. But in 1953 the same authors reported on 40 cases and more or less surprisingly, in 1/3 (13 patients) a chronic abuse of Saridon* and other analgesics wes noted: for the first time a causal connection between analgesic abuse and the syndrome of chronic interstitial nephritis with papillary necrosis and progressive renal failure was suspected (8) . Within two years Zollinger (9) had observed another series of cases and noted again that in 19 of the observed 62 cases (31%) a long period of analgesic abuse (usually Saridon) was ascertained. Some 30 years ago (in 1955) Zollinger (9) wrote: "Die phenacetinhaltigen Analgetica konnen somit nicht "nur die Sucht, sondern hochstwahrscheinlich auch "chronische Nierenschaden erzeugen, welche sich "rneist als chronische interstitielle Nephritis ..aussern....**.
The analgesic nephropathy syndrome had emerged as a new disease entity (10) .
Analgesic mixtures: addiction and nephrotoxicity
Phenacetin°aspirin mixtures became rapidly popular as common household analgesics. Because of seemingly low toxicity and low cost they soon became common remedies against headaches, backache, toothache and other trivial complaints.
Aspirin, like other salicylates, relieves pain of moderate intensity such as occurs in many muscle and joint disorders and for instance in dysmenorrhea (11) . The mood-altering side effects of phenacetin, causing relaxation, euphoria, increased energy and working power, at least in certain individuals who are sensitive to these effects, are responsible for the habit forming (11, 12) . Although phenacetin is probably not the most nephrotoxic compound (13, 14) . many clinical investigators confirmed the hypothesis of Spuhler and Zollinger. Gradually excessive analgesic consumption became recognized as a major cause of chronic renal disease (1) .
The abuse liability of phenacetin has also been confirmed in interesting and ingenious animal experiments with Rhesus monkeys (15, 16) .
Phenacetin has been traditionally marketed in mixtures with salicylates (aspirin) or phenazone and caffeine or codeine, either as tablets or as powders under a multitude of proprietary names.
The combination of salicylates with phenacetin, codeine or caffeine enhances not only the analgesic properties but probably also the mood altering qualities ("these tablets give me a lift", "codeine perks me up and makes me calmer" [17] ).
The habit forming and abuse of these analgesic mixtures and their long term nephrotoxic side effects are presently recognized as a world-wide and costly health problem and an important (potentially preventable) cause of end stage renal disease (18).
Geographic distribution of analgesic abuse and nephropathy
Although it seemed initially that the occurrence of analgesic nephropathy (AAN) was largely limited to a few countries in Europe (Switzerland, Sweden, Belgium, West Germany) and Australia and South Africa, from the growing literature it became increasingly clear that AAN is widely distributed in the industrialized countries.
As appears from Tables I-III there are large geographical variations both in consumption (and abuse) of antipyretic analgesics and in geographical distribution of analgesic nephropathy, not only from country to country but also from one region to another, in the same country and also often from year to year.
Even when one considers the often divergent figures and data from different investigators and different sources there seems to be a relationship between per capita consumption of antipyretic analgesics and the percentage of analgesic nephropathy patients in renal replacement programs, at least in some countries ( Fig. 1 ). 
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, Phenacetin gradually withdrawn from over-the-counter analgesics and consumption steadily reduced between 1962 and 1975 (20) " Prohibition of phenacetin or limitation to "on prescription only" It is clear from Tables I-III that analgesic consumption is widely distributed and that analgesic associated nephropathy is a serious health problem with important socio-economic consequences in a significant number of countries.
One should also take into account that the figures presented in Tables I-III are minimum figures: analgesic nephropathy is almost certainly often under-diagnosed: an unknown number of patients (the percentage will vary from country to country or even from one region to another) are ending up in renal replacement programs diagnosed as chronic pyelonephritis, renal stone disease or even as terminal renal failure from unknown origin.
When studyng the literature on analgesic consump-222 tion (Tab. III) in different countries often confusingly conflicting figures are noted from different investigators, because either the total amount of analgesics delivered as tablets or powders is presented or the amount of a single compound (usually phenacetin) present in the analgesic mixtures is mentioned. In addition per capita figures can be misleading: as Maher (44) pointed out total consumption of analgesic intake per population may poorly correlate with the incidence of individual abuse.
Finally drug consumption and comparisons between different countries are usually based on cost parameters and can also be seriously misleading, because of price differences, replacement by (cheap) generic alterna-per-capita-consumption 20% 15 tives and fluctuations of prices and currencies (40) . Interestinqlv, the national preferences for certain types of analgesics or analgesic mixtures are also often quite different, even in adjacent countries which have many customs in common and which are also otherwise closely related: Denmark for instance (adjacent to Northern Germany) is a consumer of phenacetin, supplemented by a small amount of aminacetophen. Sweden and Norway both prefer aminacetophen: Sweden as a monocomponent, Norway consuming nearly all of it in analgesic mixtures..... (39, 40, 43) . Finland is certainly the "cleanest" of the Scandinavian countries (39, 40) .
Mihatsch and coworkers (37) estimated the annual cost of medical care caused by end-stage analgesic nephropathy -a basically preventable disease -in a small country like Switzerland (pop. 6.3-6.5 mil.) in 1980 at over 30 million Swiss francs (that is presently approx. US$ 17 million).
It is alarming that in several countries like Belgium, Switzerland and the Federal Republic of Germany the occurrence apparently is on the increase (Tab. I), even when improved diagnostics (with the growing number of nephrologists) may playa role.
Switzerland is also afflicted by a high incidence of analgesic abuse and has the highest incidence of analgesic nephropathy in Europe (45 [Tab. I and II] ). Nationwide at least some 13-27% of the patients presented for replacement of renal function have as primary renal disease analgesic nephropathy (21, (24) (25) (26) 33) .
In Basle/St. Gallen analgesic nephropathy was diagnosed in 1-1.1 % of all autopsies during the 20 year epi- sode of 1955-1975 (46) . In Australia the highest numbers of patients are observed in the north-eastern states of the country (Queensland and New South Wales). In Australia there is also a positive correlation between the geographic distribution and the percentage of the adult population who take "a few or more" analgesic tablets or powders every day (47 [ Fig. 2] ). In Australia, nationwide, analgesic associated nephropathy is the primary renal disease in 20-24% of the patients on treatment for end-stage renal disease (2, 19, 20, 48) , in conformity with this the analgesic consumption is one of the highest in the world (Tab. III [20, 37] ).
Interesting data on consumption of non-narcotic analgesics in the Federal Republic of Germany (population 61 million) were recently presented by Pommer and Molzahn (27, 28) at two symposia on drug induced nephrotoxicity at Antwerp, Belgium (1984, '85) . Although the total sales of analgesics in the FRG decreased between 1976 and 1983 by slightly more than 7%, the sales of phenacetin and acetaminophen in the same 7 years period increased by 4.3% to 299,000 kg, mean consumption of these analgesics in mixed compounds being 6.3- and 258 out of 1400 patients (18.5%) appeared to have analgesic renal disease (22) . The consumption of non-narcotic analgesics in Belgium is (calculated as per capita/per year) one of the highest in Europe and the second highest in the world (after Australia). The prevalence of AAN (34.4 cases per million adult population on January 1, 1980) is also the highest in Europe and the second highest in the world (Tab. I-III).
In addition the remarkable distribution, the greatest incidence being in the area surrounding Antwerp, has intrigued clinical investigators.
Belgium is divided into nine districts ("provinces", see Fig. 3 ). The prevalence of AAN is highest in the province of Antwerp (100 patients per million adult population [22] ) and the adjacent province of East Flanders (mean 70 patients per million). In the central area (province of Brabant including Brussels) the incidence is less (38 patients per million population) and the prevalence is substantially lower in the remaining districts (see Tab. IV). As shown in this table the incidence of analgesic nephropathy correlates well with the sales of locally produced analgesics, manufactured at the three factories sur-• Effective April 1, 1986, phenacetin in the Federal Republic of Germany is prohibited, both in proprietary (over the counter) mixtures and in prescriptions (to be probably replaced by paracetamol).
6.5 g per capita per year (see Table III ). The investigators concluded that the consumption of non-narcotic analgesics in the FRG remained a serious health problem in the past seven years. While in older statistics analgesic nephropathy was the primary disease in only 5% of cases of end-stage renal failure in the FRG (24, 25) . the rate has increased among the new comers into dialysis programs to 15% (29) and in a large unit in West-Berlin presently in 33% of the dialysis population the primary renal disease is analgesic nephropathy (29) .
Annual sales figures of antipyretic analgesics in the FRG suggest analgesic addiction and abuse in at least 100,000 to 380,000 people (28) .
Assuming that the diagnosis in all cases of analgesic nephropathy is correctly ascertained (which is probably not the case), some 15% of all 16,720 patients on replacement therapy in 1984 had AAN as primary renal disease (49) . There must be in West Germany some 2500 patients with terminal AAN.
According to figures from out patient clinics the total number of patients with clinically manifest AAN must be some 5000 patients.
The extremely high prevalence of analgesic nephropathy in West Berlin (no figures are available from the eastern part the city) may be related to the unusual demographic features of this more or less sequestered area of the western world, which probably give rise to psychological problems and tensions in the community leading to analgesic abuse in certain persons.
It should be mentioned that in the FRG so far no restrictive legislation had been instituted, except that packages of tablets had to carry a warning informing the consumer that overconsumption is dangerous to health. This warning became compulsory in 1983*.
Still in the FRG 270 different analgesics (90 on prescription only, 180 freely available over-the-counter [29] ) were listed in 1983, 58 of them containing phenacetin and 116 paracetamol. Two thirds of the phenacetin containing analgesic drugs were sold on doctor's prescription, with a total of 54,000 kg.
Belgium. In this country, which with Switzerland and the FRG belongs to the three European countries with the highest analgesic consumption per capita, analgesic associated nephropathy is a serious problem in the northern part of the country (the Province of Antwerp).
The incidence was evaluated a few years ago by questioning all 49 adult dialysis units in Belgium; 46 replied rounding Antwerp and indicated in Figure 3 . There is also a positive correlation with the total sales of analgesics and the occurrence of analgesic nephropathy. The correlation is, however, not shared by the imported analgesics which entered the market much later and remained less popular.
In addition the imported analgesics were largely mono-compounds and (or) not containing phenacetin nor paracetamol. The locally produced products are compound mixtures containing caffeine and either sal icylates, aminopyrine (Phenazone) or phenacetin (or acetaminophen).
Compound mixtures are more liable to addiction and are also more nephrotoxic (1, 2, 51, 52) .
Similar epidemics of analgesic addiction and consequently of analgesic renal disease occurred in Western Scotland (in particular in Glasgow and its environments [17] ), in the north-west of North Carolina in the USA (53, 54) , in West Berlin (27, 28, 50) and, as discussed earlier, in southern Sweden (Husqvarna and Ji:inki:iping [5] ).
In The Netherlands (population 14 million) with 2000 dialysis patients and some 5% of them (approximately 100 patients) suffering from analgesic nephropathy (49) at least 26 over the counter analgesics are marketed, containing salicylate (usually aspirin) and acetaminophen and sometimes caffeine and (or) codeine.
Per capita consumption of phenacetin was estimated at some 4 gin 1982 (42) . Since January 1,1984 sales of phenacetin in this country either over the counter or on prescription are prohibited.
It has long been maintained that analgesic nephropathy in the USA is only a minor problem (44) or no problem at all, as in some European countries (e.g. the UK, France and Italy [see Fig. 1 and Tab. I]). Some American investigators even doubted the relation between abuse of analgesics and renal damage (3, 55 -57) .
On the other hand diagnostic accuracy has been doubted by many because of the insidious course of the renal disease and the unspectacular signs and symptoms until the patient becomes azotemic, gradually entering the uremic end-stage. In addition the denial problem (see further) when eliciting the history of analgesic ingestion which is such an important diagnostic weapon, makes the history of many patients unreliable.
Even when analgesic abuse in the USA was recognized already some 80 years ago (3, 4) . the syndrome may have been forgotten by many clinicians as sometimes occurs, and because of the difficult diagnosis, analgesic nephropathy may be easily overlooked and mislabeled.
Wing and associates (25) . using statistical data from the US Health Care Financing Administration, noted that the diagnosis of the primary renal diseases in American patients was missing in 51% of all cases.
In the USA over 50 aspirin and over 100 acetaminophen preparations were listed in 1983 (44) and some data on analgesic consumption in the USA have been reported in 1968 (38) , the average consumption being 10 g of phenacetin per capita per year nationwide. More recent data are not available in the literature.
As appears from Table III this figure seems to be in the range that has been reported from other countries where a relatively high incidence of analgesic renal disease has been established. It is, however, not clear if this figure refers to analgesic tablets or powders with mixtures, containing phenacetin or to phenacetin being the single compound.
In addition total consumption of the population may poorly correlate with individual consumption (32, 44) . Reasonably reliable figures on the prevalence of analgesic nephropathy in the USA are difficult to obtain.
Thomas G. Murray and coworkers (30, 32, 54, 56) reported in the Philadelphia area an incidence of 6-7% in all cases with chronic renal failure in 1975, some 20% of all cases of interstitial nephritis being due to analgesic nephropathy. They suggested (in 1981) that analgesic renal disease was a considerable public health problem in the USA (54) . The same group wrote earlier that the incidence seemed to increase (30) , but from a case control study conducted in south-eastern Pennsylvania and southern New Jersey they concluded that if there was an association between the use of analgesics and end-stage renal disease the risk was not large, at least not in the areas where their study was carried out (56) .
Others (31) reported in 1975 that 2-10% of a dialysis population of 150 patients in California had analgesic nephropathy. More recently (1981) Gonwa and associates (53) reported that analgesic abuse was "an important cause of chronic renal disease in North Carolina": 6- (44), citing from his own experience, thinks that the incidence of AAN is low in the USA, which is underlined by an autopsy incidence of renal papillary narcosis (a definite diagnostic criterium of AAN) of only 0.1-0.3%.
Nevertheless the answer of several clinical investigators to the question "is analgesic-associated nephropathy an important cause of renal disease in the United States" was a definite yes (31) .
Considering that analgesic nephropathy is both a preventable and treatable disease and the high cost of treatment of the end-stage it may be an important socio-economic health problem also in the USA.
Different explanations for the unequal geographic distribution
Different hypotheses in explanation of the striking unequal distribution of analgesic abuse and nephropathy have been presented.
A poor economic status of the local population could contribute to a high incidence of addiction (47) . These "antipyretic" analgesics cause relaxation and euphoria and have a stimulatory effect, in particular when mixed with salicylates and caffeine or codeine.
In addition they are cheap and they were as over-thecounter drugs easily and in unlimited quantities available in nearly every country (in several countries they are still easily obtainable without prescription). Presently in the majority of countries legal restrictions have blocked the access to phenacetin.
In several countries, however, analgesic drugs have been replaced by paracetamol, which is usually not restricted and which probably has similar effects and toxicity...
. However the high prevalence in northern Belgium cannot be attributed to a poor social economic status of the population: the provinces of Antwerp and East Flanders are the most prosperous areas of Belgium.
Vigorous sales promotion and advertising of their products by local manufacturers of analgesics seem to be the major determinants both in northern Belgium, in western Scotland (Glasgow area) and in the north-western states of Australia (17, 19, 22, 44, 45, 48) .
On the other hand, in closed communities as for instance in factories, the stimulating effect may contribute to addiction because it contributes to the ability to work quicker and to increase the output of piece-work, augmenting one's earnings. In addition addicts often stimulate others to try the "wonderful tablets (or powders)", as happened on a large scale years ago in southern Sweden (5, see above).
In some factories mixed analgesics are freely dispensed by the management (58) to satisfy the desires of the factory workers and to improve work performance (and to increase the profits of the company).
Epidemiology and personality features of the individual analgesic patient
Characteristically the majority of the patients with analgesic nephropathy are women over 30, usually in their middle age, but in closed communities (e.g. in factories) there is an equal female-male distribution or even a male preponderance (5) . the female-male ratio depending on local incidence. If not disturbed by denial there is a history of heavy analgesic consumption for 5-20 years, nearly always of mixed compounds, usually proprietary analgesics, which are sold over-the counter under innumerable fancy names.
In epidemic clustering of analgesic abuse ("community abuse") exogenic factors playa dominant role. The presence of analgesic factories with associated sales promotion by advertising in newspapers, weeklies, by TV and radio commercials are important promoting factors.
On the other hand the working conditions in industries and mutual by word of mouth encouragement by factory workers and employees or even in families at home ate probably dominant incentives for gradually spreading mass abuse (5, 22, 50, 59) .
In contrast in the individually addicted patients endogenous (psychogenic) components have to be considered as standing central in the genesis of analgesic addiction and abuse (19, 26, 36, (60) (61) (62) . Personality disorders with immaturity, dependance and emotional instability are common, often with anxiety and depression. Many patients are hypochondriacs.
The typical patient is a middle aged or younger female with a long history and a variety of complaints: headaches, backpain, abdominal symptoms or dysmennorhea, social and marital adjustment being often inadequate. Problems at work may also playa role.
Most patients started taking analgesics because of the psychotropic side effects, in particular of phenacetin (5) .
The habit of analgesic intake commences usually between the late twenties and the mid forties. The minimal analgesic consumption associated with nephropathy is estimated to be 1-2 kg of aspirin or phenacetin (or both) in a mixed compound form (29, 52) .
In Australia regular analgesic intake seems to begin earlier and starts often in secondary schools: by school leaving age the analgesic consumpion of these youngsters may be at adult level (48) .
Most patients take much more than the minimal nephrotoxic quantities, often consuming a cumulative amount of 5-10 kg over a period of between 3 and 30 years (29, 52) .
The average period of abuse (from the beginning until the start of dialysis therapy) was in a large group of patients in West-Berlin 21 ± 12 years and the average age at dialysis start was 56 ± 11 years (29) .
A dangerous vicious circle may originate from selfmedication with analgesics for common disorders. Because the average tolerance of pain in modern civilized society is rather low, people have for example headache or a painful menstruation and start taking a cheap (phenacetin containing) analgesic. The after effect may be a recurrence of the painful disorder, the patient takes the tablets again and likes the euphoric effect etc. Gradually the vicious circle is closed: the patient becomes addicted (62) . Kidney disease may develop later.
Bock (62) warned already in 1957 that abuse was promoted by the pharmaceutical industry by flooding the market with cheap over-the-counter analgesic drugs and mixtures together with heavy publicity and advertising (17, 19, 20, 22, 44, 46, 62, 63) . In the USA more than half a century ago (in 1917) Bayer aspirin was struck off the AMA listing of New and Non-official Remedies because of objectionable advertising of the product along the lines of: "It has no ill effects", "It always helps", "It never harms", "Genuine aspirin can't hurt anybody", "Any doctor will tell you that they are harmless" ... (44) . And are marketing policies presently much different?
Diagnostic problems
An early diagnosis is of crucial importance. Nevertheless it is highly probable that a substantial number of analgesic addicts with nephropathy is going undiagnosed or misdiagnosed because most patients remain asymptomatic until azotemia or even uremia develops.
On the other hand a major cause of missing the diagnosis is the propensity of the patients to deny or grossly understate their ingestion of analgesics, a frequently described phenomenon, emphasized in the literature (5, 17, 31, 32, 48, 50, 64) .
Eliciting the history of ingestion of analgesics requires a special approach and is often a time consuming procedure (48) . Even then, one has to expect a poor reliability 
Some clinical features and the course of analgesic nephropathy
As discussed earlier the individual patient is characteristically a middle aged woman with a long history of headaches, of backpains or other often psychoneurotic problems. She (or he) may complain of gastric symptoms: a gastric ulcer may be the cause or effect of anal-and reproducibility: one of the authors (A.S.) interviewed seven patients, who were known analgesic addicts, by coincidence twice. One patient indicated the same cumulative number of analgesic tablets in both interviews. In the six others there was a difference of at least 100% between the two interviews. Two patients denied any analgesic intake at one interrogation and admitted a big intake of tablets at the other interview ( Fig. 4 [50) ).
Ingestion of the common antipyretic analgesics can be detected in the urine: the main metabolite of phenacetin, N-acetyl-p-aminophenol or NAPAP = acetaminophen (=paracetamol) can be rather easily quantitatively measured (64) (65) (66) (67) (68) . The test is usually positive after ingestion of phenacetin or paracetamol during 12-24 h before the test urine is sampled.
In addition it is recommendable to test the urine specimen also for the presence of salicylates with the ferrichloride test or with a phenistix: it should be kept in mind that salicylates according to several authors may be the major nephrotoxic compound (14, 19) . gesic abuse.
In most patients clinical manifestations of renal involvement are subtle or minimal until advanced renal failure occurs. A renal colic may occur, often caused by passage of fragments of a necrotic papilla or an entire sloughed papilla. This is usually followed by gross hematuria and accompanied by fever and urinary symptoms as in acute pyelonephritis.
When analgesic abuse is continued, gradually signs of tubulo-interstitial renal dysfunction may develop and a slowly progressive loss of renal function occurs. Moderate hypertension occurs in 50-70% of the patients and is typically of the benign type. Malignant hypertension is an unusual complication.
Proteinuria is of the tubular type and is mild or moderate, usually less than 1 g per day. Occasionally a more heavy proteinuria occurs (of a mixed glomerular and tubular type, exceptionally in the nephrotic range). This is due to secondary glomerular lesions and carries a poor prognosis (2, 20) .
The urine sediment is usually uncharacteristic, containing some red cells, a few hyaline casts and some leukocytes.With increasing loss of nephrons, scarring and contraction of renal mass the uremic syndrome gradually unfolds and replacement of renal function becomes mandatory.
It should be emphasized that a "diagnosis" of chronic renal disease without further specification or even a biopsy diagnosis of "chronic interstitial nephritis, cause unknown" will derive the patient of timely and adequate therapy, that is primarily the urgent advice of discontinuing any further ingestion of analgesics. Obviously an incomplete diagnosis carries a fair chance that the patient eventually ends up as dialysis patient.
Progression of renal failure obviously manifests itself by an increase of serum creatinine and a gradual decrease of glomerular filtration rate, commonly demonstrated by a slowly progressive reduction of the creatinine clearance. The renal dysfunction is of the interstitial tubular type with an early and disproportionate reduction in concentration capacity with iso-or hyposthenuria, resistant to vasopressin (30) . As in other interstitial nephropathies hyperchloremic acidosis usually develops with or without an increased aniongap. Often renal sodium conservation is impaired (30) with signs and symptoms of sodium depletion. Patients are often anemic and the anemia may be of the normochronic, normocytic type as is commonly seen in chronic renal failure, but is frequently disproportionately more severe in comparison with the decrease of renal function. This may be caused by iron deficiency, secondary to aspirin related gastro-intestinal blood loss. Complicating stomach ulcers may be respon- The astute clinician may observe blue lips and a mild cyanosis of the central type, which is due to met-and sulfhemoglobinemia, a toxic phenomenon related to a metabolite or a contaminant of phenacetin or paracetamol, either p-phenetidine or p-chloracetanilide.
According to some investigators cyanosis and sometimes hemolysis are in particular caused by antipyrine and amidopyrine in combination with phenacetin and acetaminophen, by induction of microsomal enzyme activities.
Renal and non-renal complications
Some renal complications have been discussed before.
The most dramatic event is of course the passage of a sloughed necrotic papilla (or parts of a papilla), causing a renal colic and frank hematuria.
A similar dramatic complication may occur from the passage of a renal calculus, which may be a dislodged calcified necrotic papilla or a calcified part of it. Both may block the ureter giving cause to an acute hydronephrosis.
Another common complication is urinary tract infection with pyelonephritis. This may occur in 15-60% of patients (48) ; pyuria occurs often with negative cultures.
Non renal complications are many. An appearance of premature aging is commonly observed: it may be due to the deposition of lipofuscin pigment (46, 51) , which is a highly oxidized polymer of unsaturated fatty acids, probably related to the oxidizing effect of phenacetin. It is widely distributed in brain, heart, kidneys, skin and other tissues of analgesic patients (46) .
On the other hand premature aging also manifests itself in ischemic heart disease, cerebral vascular disease, peripheral vascular disease and other common wastages which of course are non specific common complications in patients with progressive renal failure and hypertension.
A most serious complication: malignancies of the urinary tract A relationship between malignant tumors of the urinary tract and analgesic (phenacetin) abuse was first suspected in Sweden by Hultengren and coworkers (1965 [70ll, who observed epithelial renal pelvic tumors in six patients, all with renal papillary necrosis, five of them being notorious abusers of phenacetin containing analgesics. All six patients were females. Their publication was soon followed by similar observations by Bengtsson and coworkers also from Sweden (71), who found such tumors in 9 out of 104 patients all previously known as analgesic abusers with nephropathy. Retrospectively the same investigators found in their hospital records another 29 patients with epithelial renal pelvic tumors; 14 of them had been abusers of phenacetin containing drugs, the majority of them being females. In the Huskvarna/Jonkopinq district in Sweden the case records at the local county hospital were also reviewed: 15 cases of urothelial tumors of the renal pelvis were found, being recorded in an 8 year period (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) ). Ten, possibly 12 had been abusing phenacetin containing powders.
The incidence of spontaneous renal pelvic tumors in non-abusers is very low: in Sweden the annual average incidence is approximately one case per 156,000-183,000 population, predominantly males (ratio four males to one female). This ratio, however, appeared to be reversed in renal pelvic tumors in analgesic abusers (except at the Huskvarna factory with an exclusively male working force).
Since 1965 more than 400 cases of urothelial carcinoma in patients with renal papillary necrosis have been reported (48) . With longterm survival of patients with analgesic nephropathy on dialysis therapy urothelial carcinomata may develop in 8-10% of the patients with analgesic nephropathy on dialysis. They are localized in a renal pelvis calyx, in a calyceal infundibulum, in the renal pelvic ampulla or a renal papilla. Sometimes these tumors are bilateral.
According to some clinical investigators there is also an increased risk of bladder cancer, cancer of the ureter and renal carcinoma (so called hypernephroma) in analgesics abusing patients (70) (71) (72) (73) (74) (75) .
According to Mihatsch et al (76, 77) the risk of developing cancer of the ureter is 89 times higher, the risk of renal pelvis carcinoma 77 times higher and of bladder cancer 17 times higher in patients who abuse analgesics than in patients who do not abuse.
All data strongly point to analgesic abuse as an inducing factor for the development of transitional cell cancer of the urinary tract, and phenacetin, in particular in combination with other analgesics (salicylates and others). is incriminated as being the main offender.
Several metabolic products of phenacetin, which is an aromatic amide (see foot note on p.220), in particular the 2-and N-hydroxylated metabolites, are carcinogenic in rats and probably also in man.
They are concentrated in the renal papillae (2, 31, 48, 73) , which may enhance their carcinogenic effects.
A priori one should expect similar hazards from paracetamol (= N-acetyl-p-aminophenol) which is the first metabolic conversion product from phenacetin.
The distinctive features of analgesic associated uroepithelial tumors include a female predominance (2) and an average phenacetin consumption of approximately 9 kg, a mean exposure time of 17 years and an average induction time of 22 years (71).
These patients usually have also analgesic nephropathy and papillary necrosis as common features.
The diagnosis of urothelial malignancies is often made late or too late: the main feature, gross hematuria, does often not alarm the patient nor the doctor because it is also a feature of the accompanying nephropathy with papillary necrosis.
Patient with analgesic nephropathy therefore should be followed closely and regular examination (every 3-6 months) of the urine sediment is mandatory; even if the patient is on dialysis therapy, some urine may still be available. The finding of microscopic (or gross) hematuria or abnormal, suspect cells should prompt investigation of urine cytology by an experienced cytologist. In addition urography or retrograde pyelography and endoscopy are indicated at the slightest suspicion of malignancy (71).
The so called analgesic syndrome
The toxic effects of chronic abuse of non-opiate, nonsteroid anti-inflammatory analgesics are presently well established. Several investigators have listed them together as the analgesic syndrome, which includes a number of multi-organ manifestations, presented in Table VI (13, 19, 38, 48, 52, 68) .
The syndrome has been extended with numerous nonspecific manifestations like urinary tract infections, neuro-psychogenic abnormalities, atypical migraine, the lower backpain syndrome etc.
Analgesic abuse may be complicated by other abuses, such as habitual ingestion of laxatives, sleeping pills, cigarette smoking, alcoholism and (or) the ingestion of (other) psychotropic drugs.
Depression and employment difficulties may complicate the syndrome and a fam ily history of analgesic abuse is not uncommon.
As has been discussed before, problems of social and (or) marital adaptation and for instance the double stress of running home, taking care of the family and having an exigent job may pave the way for analgesic addiction.
Persistent analgesic abuse during renal replacement therapy
Even when patients have had full information on the cause and the nature of their renal disease, a substantial percentage secretly continues their analgesic habit, even when being accepted into a renal replacement program (34, 79) . When the patient is successfully transplanted, the graft may be damaged by the continuing ingestion of analgesics. In addition continued consumption of antipyretic analgesics may promote the occurrence of urothelial malignancy (see above).
Most tragic are those patients who received their analgesics through prescriptions of their physicians, who, unaware of the renal toxicity, continue to prescribe these analgesic drugs (53) .
Etiology
The culprits: salicylates and (or) phenacetin/ paracetamol or other?
The original work of Spuhler and Zollinger and their hypothesis concerning the etiology of the syndrome (80), were soon confirmed, but controversies raged for a long time whether papillary necrosis with interstitial nephritis was simply due to the well known other causes of interstitial nephritis or to chronic excessive consumption of phenacetin containing analgesics like Saridon" or other antipyretic analgesics.
Australian investigators decided upon the issue: papillary necrosis is the primary and cardinal lesion; interstitial nephritis is the consequence of this (81) .
Renal papillary necrosis may be induced in animal experiments by aspirin and phenacetin and its primary metabolite paracetamol: all are nephrotoxic (81) .
Interestingly, it came out that in long-term animal experiments in rats moderate doses aspirin had a greater nephrotoxic effect than phenacetin or paracetamol, but the effect was less than in combination with either (68, (81) (82) (83) .
Aspirin alone (in huge doses) produces papillary necrosis and secondary cortical lesions resembling the lesions in humans, in 30% of laboratory rats.
Huge doses of phenacetin have only minor effects, producing minor changes in the renal papillae (20) .
The chronic nephrotoxicity of aspirin per se is also demonstrated by the occurrence of renal papillary necrosis and interstitial nephritis in patients with rheumatoid arthritis being treated with substantial doses (3-6 g per day) of aspirin over many years (84, 85) .
Phenacetin and paracetamol when administered as single compounds are less nephrotoxic and renal papillary necrosis with these (single) analgesics is uncommon (19, 48) .
It should be mentioned that the newer non-steroidal anti-inflammatory drugs (NSAIO's)* both in acute and chronic toxicological studies in animals and in men have also some nephrotoxic effects (19, 48, 51, 81 ) . Phenylbutazone, mefenamic acid, indomethacin and propoxyphene and many other analgesics have produced papillary necrosis in rat experiments (78) .
In practice these NSAIO's play, however, a minor role: the nephrotoxic effects are usually mild and readily reversible and on the other hand addiction and abuse do not occur: the euphoric effect, the "psychological lift" is lacking. Last but not least the NSAIO's are not freely available as over-the-counter drugs: a doctor's prescription is obligatory.
Pathology
The pathologic cornerstones of analgesic kidney disease are papillary necrosis and interstitial nephritis (80, 86) .
Papillary necrosis (see Fig. 5 ) is presently generally considered the primary lesion, which tends to be total like a cap, or central with formation of cavities in the papillae. The renal papillae appear shrunken, the color may be pale yellow to a darkened brown. The entire papilla or a part of it may become detached (sometimes forming a nidus for stone formation). The raw area or the cavities may reepithelialize. The subcapsular surface of the kidney shows both depressed areas (corresponding with atrophic areas in direct line with the underlying papillae) and raised nodules or ridges which are in continuity with Bertin's columns, hypertrophy having taken place in those areas. In the early stage only the tip of the papilla is yellow or, in the intermediate stage, the papilla is necrotic and shrunken but the cortex has not yet undergone changes and has remained smooth.
Microscopically a necrotic papilla is structureless, gradually merging .with the less damaged proximal area of the pyramid (see Fig. 6 ), where Henle's loops have undergone necrosis but the collecting ducts, at least some of them, remain intact, although their basement membranes may be altered.
The endothelium of the vasa recta is commonly necrotic and the medullary interstitial tissue is homogene-* NSAID's: Non Steroid Anti Inflammatory Drugs ous with an increase of collagen at electron microscopy staining strongly positive with PAS.
Cortical changes are non specific, consisting of loss and atrophy of convoluted tubules, interstitial fibrosis and variable numbers of inflammatory cells.
The glomeruli remain usually intact except for a mild thickening of Bowman's capsule. A few may be sclerosed.
According to Heptinstall (80) the atrophy of the cortical tubules may be consequent to the interruption of the limbs of Henle in the papillae.
The necrotic papillae may show areas of calcification or even bone formation. Calcium may also accumulate within and around degenerating cells, in particular in the ascending limbs of Henle.
Like in other organs (see above) a brown discoloration of the papillae, the pelvic muscosa and the mucosa of the urinary tract may be observed, which is due to the fat component of lipofuscin (46, 48) .
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Pathogenesis
The pathogenesis of renal papillary necrosis has been extensively studied, in particular in relation with the toxicology of aspirin, phenacetin and paracetamol (19, 48, 52, 81, (86) (87) (88) . Both aspirin and perhaps paracetamol are being concentrated in the renal papillae by the counter current mechanism. In addition the renal prostaglandin synthesis is localized in the renal papillae.
The local toxic effect of aspirin is associated with the formation of a metabolite, mediated by a mono-oxygenase which in turn is dependent on microsomal cytochrome P450. This metabolite induces (covalent) acetylation of the intracellular proteins (52) . Probably by inhibition of the hexose-monophosphate shunt a substantial reduction of renal glutathione and an inhibition of prostaglandin synthesase occurs. Consequently synthesis Of renal prostaglandin is suppressed. This implicates medullary ischemia with a decrease of renal blood flow and an increase in medullary concentrations of the nephrotoxic compounds and their metabolites.
Then necrobiosis of the loops of Henle and lesions of the vasa recta with characteristic basement membrane changes occur (analgesic micro-angiopathy [19, 48] ).
Next ischemic and cytotoxic cell necrosis occurs with changes in the papillary interstitium, resulting in papillary necrosis.
Obstruction of the tubules (Henle's loops) leads to cortical lesions with interstitial nephritis. According to Molland (51) interstitial nephritis may occur without papillary necrosis, presumably by direct local toxic effects on the tubulo-interstitial system in the cortex.
Diagnosis of analgesic nephropathy
The pitfalls of history taking in patients abusing analgesics and the clinical features of the analgesic syndrome have been discussed earlier.
Urinalysis is obviously important and special attention should be given to the passage of necrotic tissue belonging to the destructed papillae*, which is sometimes calcified. Urine samples should be repeatedly tested for Nacetyl-p-aminophenol and salicylates.
After an overnight fast a (usually fixed) urine osmolality of 400 m. osmol/I (SG 1010) points to reduced concentrating capacity and isosthenuria, which usually occur in analgesic nephropathy.
Minimal urine osmolality after an overnight fast should • In the hospitalized patient it is recommended to strain the urine through a gauze.
be normally 600-800 m. osrnol/l (SG 1015-1020). Such simple routine laboratory examinations as blood counts, hemoglobin and hematocrit, plasma creatinine and creatinine clearance are self evident.
The radiological features of papillary necrosis (both total and partial) are characteristic, serial radiologic studies are particularly useful (89) and it should be kept in mind that urography (i.v.) usually yields better diagnostic information than retrograde pyelography (90) . In the early stages of renal papillary-necrosis swelling of the papillae may be observed. Later shrinkage may occur with irregular contours and widening of the fornices and there may be less contrast density or even no filling of a calyx at all (Fig. 7a) .
Incipient detachment of the papilla is manifested by contrast penetrating in the renal parenchyma either from the fornix or from the tip of the papilla. After detachment of the totally necrotic papilla the characteristic ring shadow may be seen when the papil is still lying in the cavity of the calyx (Fig. 7b and 7c) .
After passage of the necrotic tissue through the renal pelvis and the urinary tract the characteristic club type deformity of the empty calyx is observed (Fig. 7c) .
Detached papillae may show calcification in particular when complicating infection with B. Proteus has occurred ( Fig. 8a and b) . Figure 9a shows beginning detachment of the upper papilla and in Figure 9b complete detachment is seen with the necrotic papilla still in the cavity, showing a typical triangular ring configuration. Figure 10 presents multiple typical ring shadows with irregular outlines.
In Figure 11 shredded papillae are shown, which are calcified because of alkalinisation of the urine by urea splitting B. Proteus.
The reader is referred to the original paper of Lindvall (89,90) and others (48) for more information and further 
study.
Echorenography is helpful for detection of calcified papillae or kidney stones (91) , also in the terminal stage of renal failure, when iv. urography is not possible. Finally a diagnosis of analgesic nephropathy may be supported by a renal biopsy demonstrating chronic interstitial nephritis and, when the biopsy is inadvertently (too) deep into the medulla, necrotic papillary tissue (48) .
It should, however, be mentioned that the radiological findings of papillary necrosis are by no means unique for analgesic nephropathy. Papillary necrosis may occur in diabetes mellitus. in sickle cell disease and in obstruction of the urinary tract: these conditions need to be considered in the differential diagnosis, because the radiological findings may be identical. , The diagnosis of analgesic nephropathy is sometimes difficult and may be hampered by dogged denial of chronic analgesic abuse.
When diabetes, bladder reflux, chronic urinary ob- struction and sickle cell anemia are excluded, evidence of papillary necrosis is a pathognomonic sign. Other signs are summarized in Table VII .
Some socio-economic aspects
The sales figures of compound analgesics (usually aspirin, phenacetin, paracetamol, either with or without caffeine or codein, sometimes with antipyrine or salicylamid instead of aspirin) are enormous. Figures from a few countries, including Australia, the Federal Republic of Germany and. the USA, are presented in Table VIII .
In Belgium and the Netherlands, small countries with populations of 9.4 and 14 million, some 320,000 kg resp. 280,000 kg of analgesic tablets or powders are sold annually, selling values over the drugstore counters being approximately US$ 13.4 and 17 million. Sales in the USA are worth some 86 mil ion dollars annually. Obviously substantial economic interests of the pharmaceutical industry are at stake. To a much smaller extent some parallel emerges with the tobacco industry. According to recent data analgesic nephropathy accounts for about 7 -10% of end-stage renal disease in the USA [(32) see Table I ]. If end-stage renal disease could be prevented in these patients this would save the American Medicare Program some US$ 200 million annually (18). By the end of 1984 16,000 end-stage renal disease patients were on dialysis treatment in the FRG (92) . at least 10% of them having analgesic renal disease (26) that is 1600 patients.
One dialysis in the FRG costs 400 OM, one dialysis patient costs OM 62,400 per year; treatment of 1600 patients with (basically preventable) analgesic nephropathy cost 100 million OM per year, that is at the time of writing (January 1985) US$ 41 million per year.
Australia (population 15 million) had on April 30, 1980 approximately 1120 dialysis patients, 20% of them suffering from kidneys destroyed by analgesics, total annual cost for the Australian community being US$ 3.5 to 4.5 million (20, 25) .
In Belgium (population 9.4 million) with some 2000 patients receiving dialysis therapy and some 370 pa-236 " pathognomonic diagnostic sign , at least 2 of these signs needed to establish diagnosis tients (18.5%) with analgesic nephropathy as primary disease on treatment (22, 23) , effective prevention could save the Belgian community some US$ 15 million annually.
The Netherlands (population 14 million) also with some 2000 dialysis patients (49) . but only 5% (100 patients) suffering from analgesic nephropathy, the savings would be less, but savings of some US$ 3.5 to 4 million annually would still have been worthwhile" and at least some 100 patients would have been spared the burdens of chronic dialysis treatment.
Prevention of analgesic abuse
It has now been firmly established that analgesic nephropathy is commonly caused by mixtures containing aspirin or antipyrine in combination with phenacetin or paracetamol and caffeine or codeine (48) . Presently aspirin both in animal experiments and in human pathology is considered the major nephrotoxic agent (13, 69, 82, 83) . phenacetin and paracetamol playing a synergistic role.
As has been mentioned above the NSAIO's have also some acute and chronic nephrotoxic effects, but they are less dangerous and it is obviously not possible to ban these totally from the therapeutic armament, but in most countries they can only be obtained on prescription and because of their also substantial non-renal side effects , These calculations were possible with data kindly provided by Dr. G.K. Vander Hem, professor of medicine, University of Groningen, The Netherlands and toxicity, long-term administration of large doses is usually avoided. The dangers for the kidneys are primarily from analgesic mixtures, in particular of aspirin and phenacetin and acetaminophen.
Obviously the key to prevention is to halt the inappropriate intake of antipyretic analgesics, in particular of mixtures of these compounds (68) .
In this context it should be kept in mind that patients suffering from analgesic nephropathy have been described who took only aspirin (2, 84, 93) or acetaminophen (94) . but no patients had been described in literature who had only abused phenacetin (20) .
Ironically phenacetin has been the first compound which was withdrawn from most over-the-counter analgesics (in Australia in 1962) and has been primarily prohibited later in many other countries.
On the other hand phenacetin, while not the main culprit, is generally considered to be the compound responsible for the "psychlogical lift", the euphoric sensation and therefore for habitforming and the chronic abuse of analgesic mixtures.
Different approaches to prevention have been effected in many countries. Warnings and restrictive advises have been directed to the consumers (patients) and prescribers (doctors) by educational and informative programs.
This approach was established some 25 years ago in Australia and New Zealand (47) by the Royal Australasian College of Physicians (95, 96) and the National Health and Medical Research Council of Australia (97, [1967] ), in addition phenacetin was gradually withdrawn from analgesic mixtures.
The results were questionable (47; vide infra). Programs directed to limit the danger of tobacco con-sumption and the abuse of alcohol have also had limited success so far. Similar programs against analgesic abuse, which is much less frequent and has much less social impact. will be expensive and because of the often characteristic psychiatric and psycho-neurotic patient profile (44, 47, 48, 63) largely ineffective.
In Switzerland, a country with a particularly severe analgesic problem, another approach, which may be more effective, was suggested by Kielholz in the mid-fifties (98, 99) and was repeated by Moeschlin (100) . They recommended restriction of certain dangerous analgesics or (and) compound mixtures, limiting these drugs to deliverance by prescription only or even suggesting a total ban of some by law. This however was never effected and some 30 years later (in 1985) Dubach (68) pressed the point again.
Even presently there is no ban on over-the-counter sales of analgesics in Switzerland: a prescription being required for phenacetin or acetaminophen containing drugs in large packings only.
Not surprisingly the frequency of end-stage analgesic nephropathy in Switzerland remained (and still remains) alarmingly high as appears from Table IX. Even more alarmingly, the number of patients needing replacement of renal function because of destruction of their kidneys by analgesic abuse has sustantially increased in recent years (see Tab. I).
A similar situation occurs in Belgium, where no statutory rules have been effectuated. The number of endstage analgesic patients accepted for dialysis was second highest in Europe (11% in 1980), even increasing in recent years to 18% in 1982 (Tab. I).
In the Federal Republic of Germany until recently the only statutory measure has been a warning message on packages of analgesics containing phenacetin (effected in 1981). Recently, however, (effective April1, 1986) phenacetin has been outlawed in proprietary compounds and in prescriptions.
In the USA opinions on the prevalence of analgesic addiction and analgesic nephropathy widely diverge. At least in some areas analgesic nephropathy causes a large percentage of chronic renal failure and end-stage renal disease (30, 32, 53, 54, 101, 102) .
It has been postulated that American doctors miss the diagnosis in a substantial number of cases (56, 103) . Maher (44) thinks that this is an oversimplification of the problem.
It should be kept in mind, however, that the US pharmaceutical industry has voluntarily removed phenacetin from several popular over-the-counter analgesic combinations in previous years. This may have had a favourable influence on the incidence of analgesic nephropathy in the USA on one hand, but may have contributed (and perhaps still does) to confusing results of retro-and prospective studies on the prevalence of analgesic nephropathy in this large continent on the other hand.
The National Institutes of Health of the USA recently convened a conference of experts on the subject to resolve some of the questions and the confusion (18); one of the conclusions was that there was a need to evaluate the impact of measures designed to reduce analgesic abuse on the incidence of nephropathy. An evaluation may be presently going on. So far neither legislation nor special measures have been introduced in the USA. In the UK phenacetin was withdrawn in 1980. Because of the low incidence of analgesic nephropathy in England the results will be difficult to evaluate: so far no reports have been published.
In the Netherlands phenacetin was outlawed early in 1984, both in over-the-counter proprietary mixtures and in prescriptions. Future evaluation of the results of the measure will be difficult: anticipating the withdrawal of phenacetin the pharmaceutical industry has in recent years voluntarily replaced phenacetin in over-the-counter mixtures with acetaminophen -which probably has a similar toxic effect, in particular in compound mixtures (94) .
In Finland phenacetin became a "prescription only" drug in 1962, but became totally outlawed in 1965. Sillanpaa (41) reported in 1982 a striking decline is papillary necrosis of 94% at autopsies between 1962 and 1977 (and a decline in death by kidney disease by 54%). However, in the 1960's regular dialysis therapy was introduced and in the 1970's transplantation became a powerful therapeutic tool and this may have influenced these figures.
In Sweden a warning on packings with drugs, containing phenacetin and aspirin, was implemented as early as in 1947 and in 1961 the "prescription law" became effective in Scandinavian countries, restricting phenacetin and acetaminophen to "prescription only" drugs. In Sweden the total consumption of phenacetin fell to less than 10% and remained on a low level (19, 33, 52) . The number of new patients with end-stage analgesic renal disease entering dialysis programs decreased by 50% between 1974 and 1979 (24) . After the introduction of the law, signs and symptoms of papillary necrosis became gradually less frequent and the number of new cases of analgesic nephropathy accepted for replacement of renal function, diminished after some years (33 [Tab. IX and Xl) .
In addition the number of analgesic associated uroepithelial tumors (in G6teborg) declined after 1973 (33) .
In Denmark the prevalence of papillary necrosis at autopsy also declined more than 60% during 1971 and 1975, 10 years after the prescription law came into force.
In Australia phenacetin was gradually replaced byacetaminophen and salicylamide in analgesic mixtures between 1967 and 1979.
In 1979 legislation was effected banning over-thecounter sales of analgesic mixtures, which were limited to prescription drugs (20, 104) . During this 12-year episode the restriction (and finally withdrawal of phenacetin) had no demonstrable effect on the prevalence of renal papillary necrosis (20, 105, 106) at autopsy nor on the number of patients with analgesic nephropathy, requiring replacement of renal function (107), (see Fig. 12 ), but 16 Nevertheless the ban of phenacetin caused a small decrease in total analgesic consumption (20) .
In Canada in the most popular over-the-counter analgesics including the so called "222$ tablet" containing phenacetin, aspirin, caffeine and codeine, the pharmaceutical industry replaced phenacetin voluntarily with an extra dose aspirin. This happened in 1970 and in 1973 federal legislation was enacted prohibiting the sale of phenacetin in combination with salicylates (36, 108 tions and over-the-counter sales. Sales of aspirin increased five fold between 1946 and 1974 (Canadian population doubled in this period [ Fig. 13]) . The encouraging results are shown in Figure 14 : the number of new cases of analgesic nephropathy decreased between 1970 and 1975 markedly but not to zero, which may be explained by the continuing high consumption of aspirin in mixtures with caffeine and codeine and by the substitution of phenacetin containing mixtures with monocompound tablets with acetaminophen (94, see Tab. XI).
Apparently divergent measures to prevent analgesic nephropathy have been enacted in different countries, ranging from total prohibition of phenacetin and paracetamol to warning on packings directed to consumers and doctors or to no measures at all: no uniformity has been pursued. So far data from the Scandinavian countries (Denmark and Sweden). Finland and Canada have been encouraging, suggesting a drop in the number of new cases.
Restriction of phenacetin in Canada also had encouraging results, but the effect in Australia was disappointing.
On the other hand the effect of the withdrawal of phenacetin and its substitution by paracetamol, as for instance was effected in the UK in 1980 and in 1984 in the Netherlands has to be awaited: it takes years and often decennia of analgesic abuse until nephrotoxicity becomes evident; and we also have to wait years or even decennia until evidence becomes available about nephrotoxicity of paracetamol as monocompound or in mixtures for example with salicylates.
Management of the patient with analgesic nephropathy
The corner-stone of long-term management is halting the intake of antipyretic analgesics and also avoiding other non-steroid analgesics (NSAID's) and convincingly persuading the patient to do so.
In the majority of the patients who stop analgesics, renal function either stabilizes or even improves and progression to dialysis treatment may be prevented. Sometimes dialysis treatment may even be discontinued, because residual renal function may improve when analgesics have been discontinued.
Discontinuing the analgesic abuse (under close supervision and with careful medical support) is obviously extremely important to preserve residual kidney function, even when the patient is on regular dialysis treatment, and to prevent a successful transplant from damage or 240 even destruction by toxic analgesics. Finally there is in these patients the risk of development of malignant urothelial tumors (in the renal pelvis, in the ureter or bladder [71] [72] [73] ), which may be enhanced by continuing analgesic abuse, even when the patient is on dialysis therapy or has been grafted. Strict control and support are indicated, including frequent (but irregular) monitoring of urine samples for NAPAP and salicylates.
A high fluid intake should be encouraged and general treatment should be along the common rules for treatment of chronic renal failure.
If renal failure is not too far advanced, that is when plasma creatinine is below 300-400 11 rnol/l (2.7-3.5 mg/dl) renal function may stabilize or even improve if ingestion of analgesics is definitely stopped.
However, if renal function has decreased too far and plasma creatinines are above 300-400 11 rnol/l, renal failure usually has become irreversible and usually renal function deteriorates further, in particular when the patient secretly continues analgesic consumption.
An early diagnosis and stopping analgesic intake and adequate treatment of the chronic renal disease may spare the patient the stress and burden of chronic dialysis and may spare the community the dialysis cost.
But even when the patient is on chronic dialysis therapy, residual renal function may, if analgesics are definitely halted, improve and in rare cases dialysis treatment can be ended.
Some unanswered questions
The development of analgesic nephropathy is probably much more complex than a simple long-term process of a time-dose related exposure to one or more nephrotoxic chemicals.
Why this strongly marked female preponderance? Why does one person respond to a certain exposure of a nephrotoxic chemical with papillary necrosis and progressive nephropathy and why does another individual exposed to an identical nephrotoxic chemical load stay healthy? Familial clustering of analgesic nephropathy has been repeatedly observed (5, 29, 109, 110) and the increased frequency of HLA antigen B-12 in analgesic nephropathy patients (48, 111, 112) raises the possibility that a genetic predisposition may influence the development of analgesic nephropathy.
Prescott and coworkers (69, 88, 113) studying the metabolism of phenacetin and acetaminophen, using the exfoliation of renal tubular cells as an index of tubular injury, noted a substantial increase in renal tubular cell excretion in 2 out of 9 healthy volunteers, all receiving identical test doses of phenacetin and 1 out of 8 receiving acetaminophen. They observed (unexplained) differences in plasma concentrations of acetaminophen (the major metabolite of phenacetin) even on repeated occasions in the same individual, suggesting variations in absorption or metabolism. However, it was not possible to demonstrate differences in the absorption, excretion or metabolism of phenacetin or acetaminophen, in persons showing a marked renal tubular response compared with those who did not.
Interestingly in earlier studies (82, 83) a striking increase in renal tubular cell excretion was observed in all healthy volunteers receiving test doses of aspirin (3.6 g daily/5 days), but only in 4 of 28 receiving a similar test treatment with 3.6 g per day of phenacetin.
This seems to support the conception (which was discussed earlier) that aspirin is the principle nephrotoxic agent (82, 83) , its nephrotoxicity being Only enhanced by phenacetin or acetaminophen in mixed analgesics.
Pharmacogenetic differences and possibly differences in toxicology have been described both in phenacetin and acetaminophen. Phenacetin is almost completely metabolized by oxidative O-de-ethylation and (aromatic) 2-hydroxylation.
It is presently known that in man metabolic oxydations are controlled by a single gene (114) . Actually two oxydation phenotypes can be discerned in the population: the EM's (Extensive Metabolizers) and the PM's (Poor Metabolizers). Originally these different genetic types were defined in terms of relative ability to metabolize debrisoquine (115) .
It has been demonstrated that the PM metabolizers are also relatively deficient in O-de-ethylation capacity in phenacetin and acetaminophen metabolism (114, 116) .
Could it be that in the PM-s more analgesic material (salicylates and acetaminophen) is concentrated in the renal papillary area?
Obviously the answer has to be expected from the in-vestigators in the field of pharmacogenetics.
Another so far unsolved problem: Balkan nephropathy
In the mid-fifties -soon after the recognition of analgesic nephropathy -the endemic occurrence of a similar syndrome was observed. This disease, called Balkan nephropathy, appeared to be endemic in a restricted area of approximately 3600 square miles in the flat land of the Danubian basin, where Yugoslavia, Rumania and Bulgaria meet (117) (118) (119) .
The renal lesion is also papillary necrosis with an interstitial nephritis, progressing from focal tubular atrophy with interstitial edema and mononuclear cell infiltration to interstitial fibrosis and finally to bilaterally shrunken fibrotic kidneys (117) . The disease affects the predominantly agricultural villagers, men and women equally, often in entire families.
This peak frequency occurs at ages between 30 and 40 years, the earliest functional change being an impairment in urine concentrating ability.
This disease is usually progressive with tubular (low molecular weight) proteinuria and renal tubular acidosis and leads finally to terminal renal failure and deathusually some 5 years after the diagnosis has been established, unless replacement of renal function is provided.
Several observers noted a peculiar copper-yellow color of the skin, particularly of palms and soles and malignant tumors of the urinary tract have been found, frequently in as many as 30 to 40 percent of the patients (119) .
The etiology is unknown: vigorous investigations so far have not disclosed any causative agent of this mysterious disease, wich apart from the etiology seems in many clinical aspects almost identical with analgesic nephropathy. Most puzzling, families who had left the endemic area continued to be affected, even in the second generation (119): obviously a local infectious or nephrotoxic agent seems highly improbable.
Who brings along the solution of this fascinating and provocative mystery? Summary and conclusions 1. -Addiction and abuse of antipyretic analgesics has been recognized early after the turn of this century. The incidence markedly increased and the syndrome spread over many countries in the first half of the 20th century.
2. -The syndrome and its pathology, consisting of renal papillary necrosis and tubulo-interstitial nephritis, was first described in the medical literature in the early 1950's in Switzerland by Spuhler and Zollinger, who rightly suspected chronic analgesic (Saridonr) intoxication as being the cause in their cases.
Clinically the disease is characterized by slowly progressive renal failure with renal colics from passage of necrotic papillae. Death from uremia is common unless dialyzed.
3. -The disease has been particularly prevalent in certain areas of Australia, Belgium, Western Germany, in Switzerland and some other countries. 4. -The nephrotoxic agents are mixtures of salicylates (aspirin) with phenacetin or acetaminophen. The principal nephrotoxic compound is probably aspirin -the aminophenol derivates increasing its nephrotoxicity. However, all these components alone may cause -exceptionally -the syndrome. Rarely some newer, nonsteroid analgesics (NSAID's) can also be nephrotoxic. 5. -Phenacetin has -in particular in compound mixturesmood-altering (euphoric) properties, giving rise to craving, addiction and chronic abuse. 6. -Addiction has been greatly facilitated by the overthe-counter availability of these cheap analgesic mixtures.
Mass addiction -and abuse -may occur in all kind of communities, in factories or families because of the euphoric effect, taking away fatigue and weariness and increasing productivity.
There is a relation between the per capita consumption of antipyretic analgesics and analgesic nephropathy in several countries and in certain districts.
The pattern of sales and mass consumption (and the incidence of nephropathy) is substantially promoted by the local presence of production facilities, usually accompanied by vigorous sales and advertising policies. 7. -Individual addiction usually occurs in psychoneurotic females often with social and marital problems and mental instability, often with long histories of headaches, backpains and other, often psychogenic disorders. 8. -Analgesic nephropathy is often complicated byanernia, peptic ulcer, premature aging and atherosclerosis and in 8-10% by uro-epithelial carcinoma (the so called analgesic syndrome). 9. -The diagnosis depends largely on the history of chronic abuse of analgesics, which is often doggedly denied, hampering the diagnosis. 10. -Familial occurrence and a relatively frequent occurrence of the HLA'B'2 antigen has been observed in patients with analgesic nephropathy, pointing to a genetic disposition. 11. -Timely stopping analgesic abuse (when plasma creatinine is still below 300-400 ,umol/I) may prevent 242 further progression of the renal process. Renal function may then stabilize or even improve. 12. -Early diagnosis is therefore mandatory. 13. -There is some evidence from the Scandinavian countries and from Finland and Canada that prevalence of the disease slowly decreases after legislation abandoning over the counter sales of nephrotoxic analgesics (in particular phenacetin containing compound mixtures). 14. -Balkan nephropathy, also a chronic tubulo-interstitial nephropathy with papillary necrosis and a rather frequent occurence of uro-epithelial carcinoma, closely resembles analgesic nephropathy, but is geographically limited to the flat land between the hills in the Danubian basin in the Balkans.
The etiology is unknown.
